e-learning
resources
ERJ
2013
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Why inflammatory phenotyping is necessary for successful drug evaluation in asthma and COPD
Gibson Peter G.
Source:
Eur Respir J 2013; 42: 891-892
Journal Issue:
October
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Gibson Peter G.. Why inflammatory phenotyping is necessary for successful drug evaluation in asthma and COPD. Eur Respir J 2013; 42: 891-892
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Respiratory sequelae of preterm birth across the life span
Related content which might interest you:
The need for asthma phenotyping
Source: International Congress 2017 – PG15 Asthma stratification
Year: 2017
The need for asthma phenotyping
Source: International Congress 2018 – PG17 Asthma phenotyping
Year: 2018
Role of biomarkers in the assessment and phenotyping asthma and COPD
Source: ERS Skills course - Biomarkers and functional assessment of obstructive lung diseases
Year: 2017
Potential usefulness of phenotyping in asthma and COPD
Source: ERS Skills course - Biomarkers and functional assessment of obstructive lung diseases
Year: 2017
How can we improve our assessment of inflammation in clinical studies of COPD that use bronchial biopsies?
Source: Eur Respir J 2006; 27: 248-249
Year: 2006
Can we use a biomarker to guide antibiotic treatment in severe COPD exacerbations?
Source: Breathe, 15 (4) 353; 10.1183/20734735.0257-2019
Year: 2019
Magnetocardiographic assessment of therapeutic efficacy of β2–agonists and corticosteroids in patients with COPD and bronchial asthma
Source: Annual Congress 2008 - Comorbid cardiovascular condition and therapy of asthma
Year: 2008
Translational research approaches for finding new therapeutic targets involved in viral-induced asthma and COPD exacerbation
Source: Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD
Year: 2014
Clinical clustering of COPD patients is useful to predict future COPD exacerbations
Source: International Congress 2018 – New predictors of morbidity and mortality in COPD
Year: 2018
Need for generalized criteria in evaluating the impact of new drugs in clinical trials involving patients suffering from COPD
Source: Annual Congress 2006 - Outcomes for COPD pharmacological trials: from lung function to biomarkers
Year: 2006
Is antibiotic treatment during asthma exacerbation necessary ?
Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies
Year: 2017
Is infection screening in BAL fluid useful in children with chronic obstructive airway disease unresponsive to anti-asthmatic treatment?
Source: Eur Respir J 2006; 28: Suppl. 50, 310s
Year: 2006
Baseline data and responses to oral steroid intervention in asthma and COPD: interim report from the BIOAIR EU study
Source: Annual Congress 2007 - Asthma subphenotypes
Year: 2007
Inflammatory biomarkers in the evaluation of two-year outcomes of omalizumab treatment in severe allergic asthma.
Source: International Congress 2018 – Biomarkers for evaluating asthma
Year: 2018
Ykl-40 and phenotyping of severe asthma
Source: International Congress 2019 – Immunopathological mechanisms of lung disease
Year: 2019
Comparison of residual eosinophilic inflammation in the distal airway of patients with well-controlled asthma using different drug combinations of asthma treatment
Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD
Year: 2008
Anti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge and future perspectives
Source: Eur Respir Rev 2015; 24: 594-601
Year: 2015
Small airways function: evaluation in a population of adult patients with severe asthma and potential use as a response biomarker for anti-IL5 therapy
Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept